Bladder Cancer
October 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Bladder Cancer abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Bladder Cancer. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Bladder Cancer. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Bladder Cancer every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
Authors:Zhou HH, Liu LY, Yu GH, Qu GM, Gong PY, Yu X, Yang P
Institution:Department of Pathology, Yuhuangding Hospital of Qingdao University, Yantai, P.R. China. China. China. China. China 13356997292@163.com gpy_6681258@163.com. China 13356997292@163.com gpy_6681258@163.com.
Journal:Anticancer Res. 2017 Aug;37(8):4529-4537.

2:Occupational bladder cancer: Polymorphisms of xenobiotic metabolizing enzymes, exposures, and prognosis.
Authors:Lukas C, Selinski S, Prager HM, Blaszkewicz M, Hengstler JG, Golka K
Institution:a Institute for Occupational, Social and Environmental Medicine , Castrop-Rauxel , Germany.; b Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo) , Dortmund , Germany.
Journal:J Toxicol Environ Health A. 2017;80(7-8):439-452. doi: 10.1080/10937404.2017.1304731. Epub 2017 Jul 11.

3:Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.
Authors:Phillips RM, Hendriks HR, Sweeney JB, Reddy G, Peters GJ
Institution:a Department of Pharmacy , University of Huddersfield , Huddersfield , UK. Netherlands.
Journal:Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):783-791. doi: 10.1080/17425255.2017.1341490. Epub 2017 Jul 3.

4:The Role of Robotics in the Invasive Management of Bladder Cancer.
Authors:Khetrapal P, Tan WS, Lamb B, Tan M, Baker H, Thompson J, Sridhar A, Kelly JD, Briggs T
Institution:Department of Urology, University College London Hospital at Westmoreland Street, 16-18 Westmoreland St, Marylebone, London, W1G 8PH, UK. p.khetrapal@ucl.ac.uk.; Division of Surgical and Interventional Sciences, University College London, 4th Floor, UCL Medical School Building, 21 University Street, London, WC1E 6AU, UK. p.khetrapal@ucl.ac.uk.
Journal:Curr Urol Rep. 2017 Aug;18(8):57. doi: 10.1007/s11934-017-0706-7.

5:Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment.
Authors:Hafeez S, McDonald F, Lalondrelle S, McNair H, Warren-Oseni K, Jones K, Harris V, Taylor H, Khoo V, Thomas K, Hansen V, Dearnaley D, Horwich A, Huddart R
Institution:The Institute of Cancer Research, London; The Royal Marsden NHS Foundation Trust, Sutton, Surrey. Electronic address: shaista.hafeez@icr.ac.uk.; The Royal Marsden NHS Foundation Trust, London.
Journal:Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):115-122. doi: 10.1016/j.ijrobp.2017.01.239. Epub 2017 Feb 9.

6:Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer.
Authors:Afshari M, Janbabaei G, Bahrami MA, Moosazadeh M
Institution:Department of Community Medicine, Zabol University of Medical Sciences, Zabol, Iran. University of Medical Sciences, Sari, Iran. Yazd, Iran.
Journal:PLoS One. 2017 Jun 6;12(6):e0178527. doi: 10.1371/journal.pone.0178527. eCollection 2017.

7:Emerging drugs for urothelial (bladder) cancer.
Authors:Cumberbatch K, He T, Thorogood Z, Gartrell BA
Institution:a Department of Medical Oncology , Montefiore Hospital and Medical Center , Bronx , NY , USA. , NY , USA. , NY , USA. , NY , USA.
Journal:Expert Opin Emerg Drugs. 2017 Jun;22(2):149-164. doi: 10.1080/14728214.2017.1336536. Epub 2017 Jun 12.

8:Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly.
Authors:Janssen S, Manig L, Schild SE, Rades D
Institution:Department of Radiation Oncology, University of Lubeck, Lubeck, Germany. rades.dirk@gmx.net.
Journal:Anticancer Res. 2017 Jun;37(6):3287-3290.

9:Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Authors:Farina MS, Lundgren KT, Bellmunt J
Institution:Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA. USA. USA. joaquim_bellmunt@dfci.harvard.edu. 08003, Barcelona, Spain. joaquim_bellmunt@dfci.harvard.edu.
Journal:Drugs. 2017 Jul;77(10):1077-1089. doi: 10.1007/s40265-017-0748-7.

10:UBC(R) Rapid Test for detection of carcinoma in situ for bladder cancer.
Authors:Ecke TH, Weiss S, Stephan C, Hallmann S, Barski D, Otto T, Gerullis H
Institution:1 Department of Urology, HELIOS Hospital Bad Saarow, Bad Saarow, Germany. Health Sciences, Carl von Ossietzky University, Oldenburg, Germany.
Journal:Tumour Biol. 2017 May;39(5):1010428317701624. doi: 10.1177/1010428317701624.

11:Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma.
Authors:Chargari C, Haie-Meder C, Guerin F, Minard-Colin V, de Lambert G, Mazeron R, Escande A, Marsolat F, Dumas I, Deutsch E, Valteau-Couanet D, Audry G, Oberlin O, Martelli H
Institution:Brachytherapy Unit, Department of Radiotherapy, Gustave Roussy, Villejuif, France; Institut de Recherche Biomedicale des Armees, Bretigny-sur-Orge, France; French Military Health Service Academy, Ecole du Val-de-Grace, Paris, France. Electronic address: cyrus.chargari@gustaveroussy.fr.; Brachytherapy Unit, Department of Radiotherapy, Gustave Roussy, Villejuif, France.; Department of Pediatric Surgery, Bicetre Hospital, Hopitaux Universitaires Paris Sud, Assistance Publique des Hopitaux de Paris, Le Kremlin-Bicetre, France.; Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France.; Brachytherapy Unit, Department of Radiotherapy, Gustave Roussy, Villejuif, France; Faculte de Medecine Paris Sud, Universite Paris Sud, Universite Paris Saclay, Paris, France.
Journal:Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):352-359. doi: 10.1016/j.ijrobp.2017.02.026. Epub 2017 Feb 21.

12:A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.
Authors:Sun F, Zhao R, Zhu Y, Cui D, Wang X, Han B, Liang S, Liu H, Sun X, Zhao F, Xu D, Xia S
Institution:Shanghai General Hospital, Shanghai, China.
Journal:Cancer Chemother Pharmacol. 2017 Jun;79(6):1099-1107. doi: 10.1007/s00280-017-3305-x. Epub 2017 Apr 18.

13:Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Authors:Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR
Institution:Girish S. Kulkarni, Thomas Hermanns, Yanliang Wei, Bimal Bhindi, Raj Satkunasivam, Paul Athanasopoulos, Peter J. Bostrom, Kathy Li, Arnoud J. Templeton, Srikala S. Sridhar, Peter Chung, Robert G. Bristow, Michael Milosevic, Padraig Warde, Neil E. Fleshner, Michael A.S. Jewett, Shaheena Bashir, and Alexandre R. Zlotta, Princess Margaret Cancer Center, University Health Network, University of Toronto; Cynthia Kuk and Alexandre R. Zlotta, Mount Sinai Hospital, University of Toronto; Theodorus H. Van Der Kwast, University Health Network, University of Toronto, Toronto, ON, Canada.
Journal:J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14.

14:Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer.
Authors:Kusaka A, Hatakeyama S, Hosogoe S, Hamano I, Iwamura H, Fujita N, Fukushi K, Narita T, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ito H, Yoshikawa K, Kawaguchi T, Ohyama C
Institution:Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562, Japan.
Journal:Med Oncol. 2017 May;34(5):90. doi: 10.1007/s12032-017-0955-9. Epub 2017 Apr 10.

15:Tackling non-muscle invasive bladder cancer in the clinic.
Authors:Woldu SL, Sanli O, Lotan Y
Institution:a Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA. Dallas , TX , USA. Istanbul , Turkey. Dallas , TX , USA.
Journal:Expert Rev Anticancer Ther. 2017 May;17(5):467-480. doi: 10.1080/14737140.2017.1313119. Epub 2017 Apr 11.

16:The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.
Authors:Pietzak EJ
Institution:Division of Urology, Department of Surgery, University of Pennsylvania Health System, 3rd Floor, West Pavilion, 3400 Civic Center Boulevard, Philadelphia, PA, USA. Eugene.Pietzak@gmail.com.
Journal:Curr Urol Rep. 2017 May;18(5):39. doi: 10.1007/s11934-017-0685-8.

17:Management of Voiding Dysfunction After Female Neobladder Creation.
Authors:Hoy NY, Cohn JA, Kowalik CG, Kaufman MR, Stuart Reynolds W, Dmochowski RR
Institution:Division of Urology, University of Alberta, Edmonton, AB, Canada.; Department of Urologic Surgery, Vanderbilt University Medical Center, 1302A Medical Center North, Nashville, TN, 37232, USA. joshua.cohn@vanderbilt.edu.
Journal:Curr Urol Rep. 2017 May;18(5):33. doi: 10.1007/s11934-017-0682-y.

18:Precision surgery and genitourinary cancers.
Authors:Autorino R, Porpiglia F, Dasgupta P, Rassweiler J, Catto JW, Hampton LJ, Lima E, Mirone V, Derweesh IH, Debruyne FMJ
Institution:Urology Institute, University Hospitals, Case Western Reserve University, Cleveland, OH, USA. Electronic address: ricautor@gmail.com. Electronic address: porpiglia@libero.it. prokarurol@gmail.com. Heidelberg, Germany. Electronic address: jens.rassweiler@slk-kliniken.de. address: j.catto@sheffield.ac.uk. Electronic address: lance.hampton@vcuhealth.org. University of Minho, and Department of CUF Urology, Braga, Portugal. Electronic address: estevaolima@ecsaude.uminho.pt. mirone@unina.it. address: iderweesh@gmail.com. f.debruyne@uroweb.org.
Journal:Eur J Surg Oncol. 2017 May;43(5):893-908. doi: 10.1016/j.ejso.2017.02.005. Epub 2017 Feb 20.

19:Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy.
Authors:Waingankar N, Mallin K, Smaldone M, Egleston BL, Higgins A, Winchester DP, Uzzo RG, Kutikov A
Institution:Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA.
Journal:BJU Int. 2017 Aug;120(2):239-245. doi: 10.1111/bju.13804. Epub 2017 Mar 10.

For a FREE PREVIEW of the Medifocus Guidebook on Bladder Cancer click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Bladder Cancer click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Bladder Cancer...
at a Special 20% Discount


Medifocus Guidebook on Bladder Cancer

Updated: June 20, 2017
167 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Bladder Cancer is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

BC72706625

Coupon Expires: December 18, 2017



What Our Customers Are Saying...

"My father, a veterinarian, was recently diagnosed with invasive bladder cancer. In wondering how best to support him, I decided to gift him a copy of the MediFocus Guidebook on Bladder Cancer. I knew it would appeal to his "scientific side". I wrote a loving and personal message in the Guide to remind him how much I loved him and then gave it to him. After reading the Guide, he took it to his Urologist and was able to generate excellent and candid questions about his condition."
R.R.
Modesto, California


"This Medifocus Guidebook was significantly helpful at a time that we needed information quickly. We felt we gained information that offered us insight on what to ask our physician, as well as a preview of options on treatment and risk factors that he would probably discuss with us. Emotionally, it's a 'god-send' to look up and receive information immediately. Thanks."
L.H.S.
Crestview, Florida



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.